NCT06188741 2026-03-12
NF114
University of Alabama at Birmingham
Phase 2 Recruiting
Clinical Trials
5 trialsNCT02407405 2026-03-05
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06541847 2025-11-21
INSPIRE-NF1
Healx Limited
Phase 2 Recruiting
NCT03962543 2025-08-07
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed